News

The increase in net loss during the first quarter of 2009, against first quarter of 2008, reflects increased general and administrative expenses and expenses associated with the planned

Revenues of $26.3 million for the fourth quarter, down 1% over last year’s comparable quarter. Veterinary sales in North America of $16.5 million for the fourth quarter, up

Company Outlook IRIS International reaffirms initial guidance for full year 2009, anticipating revenue growth to at least $102 million and earnings of at least $0.48 per fully diluted

On a consolidated basis, first quarter net revenues grew 7.0% (13.8% excluding the impact of foreign exchange), operating margin was 12.7%, and diluted EPS of $0.63 met our

“On behalf of the MediGene Supervisory Board, I would like to thank Dr Peter Heinrich for his long time and successful leadership as Chief Executive Officer of the

Ferring Pharmaceuticals, a biopharmaceutical company, has launched a Phase IIIb clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone receptor antagonist approved by the FDA for

The Netherlands-based biotechnology company Pharming Group has reported that its wholly owned subsidiary DNage has received a notice from the FDA that its product Prodarsan has obtained an

Peregrine Pharmaceuticals, a biopharmaceutical company, has reported that updated preliminary data from its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer

Visiogen, a developer of products for cataract and refractive patients, has raised $40 million from new and current investors to support the global commercialization of the Synchrony dual